These results suggest that the prior treatment of HTB4 and HTB9 bladder cancer cells with the HDAC inhibitor VPA sensitizes these bladder cancer cells to the anticancer drug cisplatin. The gene discussed is HDAC9; the disease is urinary bladder cancer.